Article Versions Notes

Pignochino Y, Crisafulli G, Giordano G, Merlini A, Berrino E, Centomo ML, Chiabotto G, Brusco S, Basiricò M, Maldi E, et al. PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. Cancers. 2021; 13(24):6295. https://doi.org/10.3390/cancers13246295

Pignochino, Ymera, Giovanni Crisafulli, Giorgia Giordano, Alessandra Merlini, Enrico Berrino, Maria Laura Centomo, Giulia Chiabotto, Silvia Brusco, Marco Basiricò, Elena Maldi, and et al. 2021. "PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study" Cancers 13, no. 24: 6295. https://doi.org/10.3390/cancers13246295

Pignochino, Y., Crisafulli, G., Giordano, G., Merlini, A., Berrino, E., Centomo, M. L., Chiabotto, G., Brusco, S., Basiricò, M., Maldi, E., Pisacane, A., Leuci, V., Sangiolo, D., D’Ambrosio, L., Aglietta, M., Kasper, B., Bardelli, A., & Grignani, G. (2021). PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. Cancers, 13(24), 6295. https://doi.org/10.3390/cancers13246295